The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A potent and selective pan-RAS inhibitor, ADT-1004, targeting complex KRAS mutations for pancreatic cancer.
 
Gary Piazza
Stock and Other Ownership Interests - ADT Pharmaceuticals LLC
Consulting or Advisory Role - ADT Pharmaceuticals LLC
Patents, Royalties, Other Intellectual Property - ADT Pharmaceuticals
 
Reddy DS Bandi
No Relationships to Disclose
 
Jeremy B Foote
No Relationships to Disclose
 
Adam B Keeton
Stock and Other Ownership Interests - ADT Pharmaceuticals LLC
Consulting or Advisory Role - ADT Pharmaceuticals LLC
Patents, Royalties, Other Intellectual Property - ADT Pharmaceuticals
 
Tyler Ernest Mattox
Employment - Caris Life Sciences
Stock and Other Ownership Interests - Caris Life Sciences
 
Xi Chen
Stock and Other Ownership Interests - ADT Pharmaceuticals LLC
Consulting or Advisory Role - ADT Pharmaceuticals LLC
Patents, Royalties, Other Intellectual Property - ADT Pharmaceuticals
 
Yulia Maxuitenko
No Relationships to Disclose
 
Upender Manne
No Relationships to Disclose
 
Michael R Boyd
Stock and Other Ownership Interests - ADT Pharmaceuticals LLC
Consulting or Advisory Role - ADT Pharmaceuticals LLC
Patents, Royalties, Other Intellectual Property - ADT Pharmaceuticals
 
Donald J Buchsbaum
No Relationships to Disclose
 
Bassel F. El-Rayes
Honoraria - Charles River Associates
Consulting or Advisory Role - AstraZeneca; Bristol Myers Squibb Foundation; Exelixis; Genentech; QED Therapeutics; QED Therapeutics; Seagen; Stemline Therapeutics; Taiho Oncology; Taiho Oncology
Speakers' Bureau - Intellisphere
Research Funding - Adaptimmune (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Boston Biomedical (Inst); Boston Biomedical (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Covance (Inst); Five Prime Therapeutics (Inst); Hoosier Cancer Research Network (Inst); ICON Clinical Research (Inst); IQvia (Inst); MedImmune (Inst); Merck (Inst); Merck (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Wayne State University (Inst); Xencor (Inst); Zymeworks (Inst)
Other Relationship - ERYTECH Pharma; Exelixis; SC Liver Research Consortium